Cytokine-functionalized Synthetic Dendritic Cells for T Cell Targeted Immunotherapies: Eggermont LJ, Hammink R, Blank KG, Rowan AE, Tel J, and Figdor CG.; Adv. Therap, 2018, DOI1800021.
Controlling T-cell activation with synthetic dendritic cells using the multivalency effect: Hammink, R, Mandal, S, Eggermont, L, Nooteboom, M, Willems, P, Tel J, Figdor CG, Blank K, and Rowan AE; ACS Omega, 2017, 2 (3), 937.
Affinity-Based Purification of Polyisocyanopeptide Bioconjugates: Hammink R, Eggermont LJ, Zisis T, Tel J, Figdor CG, Rowan AE, and Blank KG.; Bioconj. Chem., 2017, 28 (10), 2560.
Polymer-Based Synthetic Dendritic Cells for Tailoring Robust and Multifunctional T Cell Responses: Mandal S, Hammink R, Tel J, Eksteen-Akeroyd ZH, Rowan AE, Blank K, and Figdor CG; ACS Chem. Biol. 2015, 10 (2), 485.
Therapeutic nanoworms: towards novel synthetic dendritic cells for immunotherapy: Mandal S, Eksteen-Akeroyd Z, Jacobs MJ, Hammink R, Koepf M, Lambeck A J, van Hest JCM, Wilson C J, Blank K, Figdor CG, and Rowan AE; Chem. Sci. 2013, 4 (11), 4168.